검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab)) AstraZeneca·Hepatocellular Carcinoma ORR 37.4% |
|---|---|
Overview Program | STRIDE (durvalumab + tremelimumab) |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Advanced Unresectable Hepatocellular Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma.. Hepatocellular carcinoma (HCC) shows heterogeneous responses to treatment with immune checkpoint inhibitors, and predictive biomarkers for dual immune checkpoint blockade remain insufficiently defined. The STRIDE regimen, combining tremelimumab and dur… |
Clinical Primary efficacy | ORR 37.4% |
Clinical ORR | 37.4% |
Clinical Result source | ClinicalTrials.gov NCT02542293 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab)) AstraZeneca·Hepatocellular Carcinoma ORR 37.4% |
|---|---|
Overview Program | STRIDE (durvalumab + tremelimumab) |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Advanced Unresectable Hepatocellular Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma.. Hepatocellular carcinoma (HCC) shows heterogeneous responses to treatment with immune checkpoint inhibitors, and predictive biomarkers for dual immune checkpoint blockade remain insufficiently defined. The STRIDE regimen, combining tremelimumab and dur… |
Clinical Primary efficacy | ORR 37.4% |
Clinical ORR | 37.4% |
Clinical Result source | ClinicalTrials.gov NCT02542293 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교